

NCIC CLINICAL TRIALS GROUP

**PANCREATIC DISEASE ORIENTED GROUP -
PDOG****AGENDA****OPEN SESSION**

Venue: Hilton Montreal Bonaventure Hotel, Montreal

Room: Salon Verriere

Date: Saturday, April 29th, 2006

Time: 3:00 pm – 4:30 pm

Chair: Dr. Malcolm Moore

3:00 pm **WELCOME AND INTRODUCTION** Dr. M. Moore

3:05 pm **UPDATE OF RECENTLY CLOSED TRIALS**

PAC.1 (SWOG-S0205): A Randomized Placebo Controlled Study of Cetuximab plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

PAC.2 (ECOG-E4201): A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer

PA.4: A Phase III, Multi-centre, Double-Blind, Placebo-Controlled Study of AMG 706 plus Gemcitabine and Erlotinib in Patients with Unresectable Locally Advanced or Metastatic Pancreatic Cancer

3:15 pm **UPDATE OF ACTIVE TRIALS** Dr. M. Moore

PA.2 (ESPAC-3): Adjuvant Chemotherapies in Resectable Pancreatic Cancer.

3:20 pm **UPDATE OF STUDIES AVAILABLE ON CTSU MENU** Dr. M. Moore

ECOG – E2204: An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely-Resected Pancreatic Carcinoma

3:25 pm **NEW PROPOSALS & DISCUSSION**

ADJUVANT

LOCALLY ADVANCED/NEOADJUVANT

METASTATIC

GI INTERGROUP UPDATE